Novartis Exelon Promotion Cited By FDA For Unsubstantiated Superiority Claims To Aricept
This article was originally published in The Pink Sheet Daily
Executive Summary
Professional file card for the Alzheimer's medication is misleading because it is based on an inadequate study, FDA warning letter says.